Publication Name	World Journal of Diabetes
Manuscript ID	68434
Country	Greece

Received	2021-05-23 09:37
Peer-Review Started	2021-05-23 09:42
First Decision by Editorial Office Director	2021-06-16 14:31
Return for Revision	2021-06-16 14:31
Revised	2021-06-22 14:06
Publication Fee Transferred
Second Decision by Editor	2021-09-06 03:01
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2021-09-06 10:55
Articles in Press	2021-09-06 10:55
Edit the Manuscript by Language Editor
Typeset the Manuscript	2021-10-11 04:15
Publish the Manuscript Online	2021-10-13 08:37

ISSN	1948-9358 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Letter to the Editor
Article Title	Non-alcoholic fatty liver disease, diabetes medications and blood pressure
Manuscript Source	Invited Manuscript
All Author List	Ioannis Ilias and Costas Thomopoulos
ORCID	Author(s) ORCID Number Ioannis Ilias http://orcid.org/0000-0001-5718-7441 Costas Thomopoulos http://orcid.org/0000-0002-8491-6029
Funding Agency and Grant Number
Corresponding Author	Ioannis Ilias, MD, PhD, Consultant Physician-Scientist, Department of Endocrinology, Diabetes and Metabolism, Elena Venizelou Hospital, 2, El Venizelou Square, Athens 11521, Greece. iiliasmd@yahoo.com
Key Words	Antidiabetic drugs; Blood pressure reduction; Non-alcoholic fatty liver disease; Sodium glucose cotransporter 2; Alanine aminotransferase; Aspartate aminotransferase
Core Tip	All new glucose-lowering agents reduce liver enzyme levels. Additionally, sodium glucose cotransporter 2 inhibitors can reduce both systolic and diastolic blood pressure (BP) by 3.5/1 mmHg, respectively, while glucagon-like peptide-1 agonist treatment was accompanied by systolic BP reduction of 1 mmHg. Whether this previous finding can be extended to non-alcoholic fatty liver disease (NAFLD) patients, in whom a bidirectional association of NAFLD measures and BP has been also demonstrated, remains by and large unknown.
Publish Date	2021-10-13 08:37
Citation	Ilias I, Thomopoulos C. Non-alcoholic fatty liver disease, diabetes medications and blood pressure. World J Diabetes 2021; 12(10): 1809-1811
URL	https://www.wjgnet.com/1948-9358/full/v12/i10/1809.htm
DOI	https://dx.doi.org/10.4239/wjd.v12.i10.1809

Full Article (PDF)	WJD-12-1809.pdf
Full Article (Word)	WJD-12-1809.docx
Manuscript File	68434_Auto_Edited-MLS.docx
Answering Reviewers	68434-Answering reviewers.pdf
Audio Core Tip	68434-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	68434-Conflict-of-interest statement.pdf
Copyright License Agreement	68434-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	68434-Language certificate.pdf
Peer-review Report	68434-Peer-review(s).pdf
Scientific Editor Work List	68434-Scientific editor work list.pdf
CrossCheck Report	68434-CrossCheck report.pdf